- Home
- PGEN vs SMTI Comparison
PGEN vs SMTI Comparison
Compare PGEN & SMTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PGEN | SMTI |
|---|---|---|
| Founded | 1998 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 182.6M |
| IPO Year | 2013 | 2008 |
Fundamental Metrics
Financial Performance| Metric | PGEN | SMTI |
|---|---|---|
| Price | $4.10 | $17.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $8.33 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 5.2M | 65.1K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $230,981,000.00 | $15,586,976.00 |
| Revenue This Year | $1,115.92 | $17.31 |
| Revenue Next Year | $81.04 | $12.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.47 |
| 52 Week Low | $1.23 | $16.05 |
| 52 Week High | $5.47 | $35.70 |
Technical Indicators
Market Signals| Indicator | PGEN | SMTI |
|---|---|---|
| Relative Strength Index (RSI) | 57.90 | 37.09 |
| Support Level | $4.02 | $16.05 |
| Resistance Level | $4.44 | $21.14 |
| Average True Range (ATR) | 0.32 | 1.18 |
| MACD | 0.12 | -0.03 |
| Stochastic Oscillator | 83.08 | 22.97 |
Price Performance
Historical ComparisonAbout PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
About SMTI Sanara MedTech Inc.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.